<DOC>
	<DOCNO>NCT00081068</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody , alemtuzumab , locate tumor cell either kill deliver tumor-killing substance without harm normal cell . PURPOSE : This phase II trial study well alemtuzumab work treat patient Waldenstrom 's macroglobulinemia .</brief_summary>
	<brief_title>Alemtuzumab Treating Patients With Waldenstrom 's Macroglobulinemia</brief_title>
	<detailed_description>OBJECTIVES : - Determine objective response patient Waldenstrom 's macroglobulinemia treat alemtuzumab . - Determine time treatment failure patient treat drug . - Determine toxicity drug patient . OUTLINE : This multicenter study . Patients receive alemtuzumab IV 2 hour day 1 , 3 , 5 week 1-6 ( course 1 ) absence disease progression unacceptable toxicity . Patients complete response undergo observation . Patients stable disease minor partial response receive additional course alemtuzumab , administer course 1 , week 7-12 . Patients follow every 6 month 2 year . PROJECTED ACCRUAL : A total 13-27 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis Waldenstrom 's macroglobulinemia ( lymphoplasmacytic lymphoma ) Immunoglobulin ( Ig ) M , IgG , IgA paraprotein Measurable monoclonal paraprotein Failed least 1 prior firstline therapy ( alkylator agent , nucleoside analogue , rituximab ) CD52positive tumor determine either bone marrow immunohistochemistry flow cytometry PATIENT CHARACTERISTICS : Age Over 18 Performance status ECOG 02 Life expectancy At least 6 month Hematopoietic Absolute neutrophil count ≥ 500/mm^3 Platelet count ≥ 25,000/mm^3 Hepatic SGOT ≤ 2.5 time upper limit normal ( ULN ) Bilirubin ≤ 2.5 time ULN Renal Creatinine ≤ 2.5 mg/dL ( &gt; 2.5 mg/dL allow due disease ) Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective doublemethod contraception 6 month study participation No serious comorbid disease No uncontrolled bacterial , fungal , viral infection No active malignancy PRIOR CONCURRENT THERAPY : Biologic therapy See Disease Characteristics No prior alemtuzumab More 3 month since prior monoclonal antibody therapy Chemotherapy See Disease Characteristics More 21 day since prior chemotherapy Endocrine therapy More 21 day since prior steroid therapy Radiotherapy More 21 day since prior radiotherapy Surgery Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Waldenström macroglobulinemia</keyword>
</DOC>